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Research
AbstrACt
Objective This article reviews and compares four 
commonly used approaches to assess patient 
responsiveness with a treatment or therapy (return to 
normal (RTN), minimal important difference (MID), minimal 
clinically important improvement (MCII), OMERACT-OARSI 
[Outcome Measures in Rheumatology—Osteoarthris 
Reseach Society International] (OO)) and demonstrates 
how each of the methods can be formulated in a multilevel 
modelling (MLM) framework.
Design Cohort study.
setting A cohort of patients undergoing total hip and knee 
replacement were recruited from a single UK National 
Health Service hospital.
Population 400 patients from the Arthroplasty Pain 
Experience cohort study undergoing total hip (n=210) and 
knee (n=190) replacement who completed the Intermittent 
and Constant Osteoarthritis Pain questionnaire prior to 
surgery and then at 3, 6 and 12 months after surgery.
Primary outcomes The primary outcome was 
defined as a response to treatment following total hip 
or knee replacement. We compared baseline scores, 
change scores and proportion of individuals defined as 
‘responders’ using traditional and MLM approaches with 
patient responsiveness.
results Using existing approaches, baseline and change 
scores are underestimated, and the variance of baseline 
and change scores overestimated in comparison with MLM 
approaches. MLM increases the proportion of individuals 
defined as responding in RTN, MID and OO criteria 
compared with existing approaches. Using MLM with the 
MCII criteria reduces the number of individuals identified 
as responders.
Conclusion MLM improves the estimation of the SD of 
baseline and change scores by explicitly incorporating 
measurement error into the model and avoiding regression 
to the mean when making individual predictions. Using 
refined definitions of responsiveness may lead to a 
reduction in misclassification when attempting to predict 
who does and does not respond to an intervention and 
clarifies the similarities between existing methods.
IntrODuCtIOn
Joint replacement is an increasingly common 
elective procedure worldwide1–3 and 
improving patient-reported outcomes after 
joint replacement is a key research priority due 
to the high prevalence of poor outcomes after 
joint arthroplasty.4 Poor outcomes include 
continuing pain, functional limitations5 and 
increased healthcare utilisation.6 However, 
there is some debate on how the efficacy of 
interventions can be judged due to the variety 
of different outcomes used in orthopaedic 
research.7–18 Traditionally, objective primary 
outcomes such as prosthetic survivorship and 
mortality rates were used.19 However, more 
recently there has been a shift in focus which 
ensures that patients’ perspective is central to 
the assessment of intervention success.20 Many 
studies now use patient-reported outcome 
measures (PROMs) as endpoints, and these 
strengths and limitations of this study
 ► Four different approaches to patient responsiveness 
can be unified into a multilevel model.
 ► A multilevel model framework of patient 
responsiveness highlights the similarities and 
differences between existing methods.
 ► Multilevel models provide a simple framework 
which incorporates measurement error and non-
linear change in trajectories of patient recovery.
 ► Multilevel models are technically more demanding 
than existing formulations of patient responsiveness, 
and convergence is not guaranteed.
 ► Multilevel models does not improve the arbitrary 
placement of the thresholds that define 
responsiveness in comparison with existing 
methods.
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tools can assess a variety of health outcomes, including 
pain,7 21 physical functioning,7 mental well-being22 and 
health-related quality of life.23
Although PROMs are widely used,4 there is still 
debate in how the results should be interpreted and 
how to define a clinically meaningful change.24–35 From 
a measurement perspective, the ability to estimate if a 
change has occurred depends on the application of an 
appropriate statistical model. From a clinical perspective, 
some authors suggest that the average statistical change 
is insufficient to ‘tell you anything about an individual’s 
chances of improving’.36 Therefore, the utility of simple 
statistical analyses are limited when attempting to help 
patients weigh up the risks and benefits of undergoing 
surgery.
To supplement simple statistical analysis, many 
researchers attempt to dichotomise the population into 
those who have or have not responded to an interven-
tion, creating a two-stage process of defining an outcome. 
There are a number of different methods (definitions) 
that can be used to dichotomise the population, and these 
secondary analyses are collectively referred to as respon-
siveness analyses.36 Four substantively different methods 
of estimating the proportion of individuals who respond 
to an intervention have been previously identified in 
orthopaedic research36: (1) return to normal (RTN), 
(2) distribution-based minimally important difference 
(MID), (3) anchor-based minimal clinically important 
difference (MCII) and (4) the OMERACT-OARSI 
(OO) responder criteria. The first three approaches 
are generic and used in many fields of health research, 
whereas the fourth approach is specific to orthopaedic 
research, but in principle could be used in many fields 
of health research.
Each of these approaches is often thought to be meth-
odologically distinct. However, all of the methods can be 
shown to be special cases of a multilevel model (MLM). 
MLM have been used in a wide variety of contexts ranging 
from growth modelling to modelling educational data. 
One of the principal reasons to use MLM is to take 
advantage of the direct estimation of different variance 
components37 and provide efficient and unbiased esti-
mates of fixed and random effects.38
Despite a number of extensive reviews of patient respon-
siveness,31 33 39 40 we will describe these four approaches 
to calculating responsiveness and highlight the substan-
tively different decisions each method makes. We will 
then describe how each approach can be translated into a 
MLM framework, emphasising the benefits of the transla-
tion and contrast the approaches using an example from 
the APEX (Arthroplasty Pain Experience)cohort study.41
MethODs
We outline the four existing approaches to patient 
responsiveness previously used in orthopaedic research36 
and describe their potential limitations and how they can 
be formulated in an MLM framework.
review of existing approaches to responsiveness
Return to normal (RTN)26 suggests that an individual has 
returned to ‘normal’ if their score on a postintervention 
outcome is greater than 2 SDs from the mean baseline 
response.
The use of 2 SD appears to be justified on theoretical 
grounds; however, it is quite arbitrary. Assuming scores are 
normally distributed and measured without error, 2 SDs 
corresponds to a 95.5% prediction interval for the mean, 
which is similar to the equally arbitrary and much-criti-
cised significance threshold p=0.05 (type I error=0.05) 
criterion used throughout medical research.42 43 However, 
there is no reason why a 1.6 or a 2.6 SD cut-offs should 
not be used in preference, which corresponds to 90% and 
99% prediction intervals.
The method also assumes the observed change is 
unlikely to be due to chance alone and does not account 
for any uncertainty. To alleviate this problem the use of 
the Relative Change Index (RCI) was proposed to be 
used in conjunction with the RTN classification.24 27 The 
RCI constructs a test of the individual’s score at follow-up 
compared with their baseline, where the SE of the differ-
ence is estimated indirectly using the SD of the baseline 
score and an assumed reliability coefficient from empir-
ical research or a range of reliability values in the spirit of 
a sensitivity analysis.
A commonly described distribution-based minimally 
important difference (MID) method classifies individuals 
as responders if their observed change is greater than 
a fixed proportion of the SD of the presurgery score.30 
There has been much debate about the exact size, or 
proportion, of the SD change score to use; however, 0.5 
SDs have been reported widely and suggested to be a 
difference that is minimally perceptible to patients.30 Any 
individual with a change score greater than 0.5 SD of the 
baseline score is defined as responding to the treatment. 
Similar to the RTN criteria, the decision to use 0.5 is arbi-
trary and there is no reason why more or less stringent 
criteria of 0.25, 1 or 2 SDs could not be used. Additionally, 
there is no reason why a test such as the RCI should not 
be conducted to check that change is beyond the bounds 
of measurement error.
Anchor-based minimal clinically important improve-
ment (MCII) is similar to the MID approach, in that it 
defines an individual as a responder based on their 
individual change score. However, the cut point is deter-
mined in individuals who report themselves as having an 
outcome which is either good/satisfactory or perceived 
as improved from baseline using an external anchoring 
question. The authors proposed using a cut point at 
the 75th centile of the change score in those who are 
satisfied.34 Therefore any individuals, whether they are 
satisfied or not, who has a change score greater than the 
75th centile are defined as responders. A closely related 
anchor-based metric is the patient acceptable symptom 
state (PASS),35 the construction is similar to that of the 
MCII with the exception that it is based on the final score 
of patients opposed to change. Conceptually, the PASS is 
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more closely related to the RTN definition of responsive-
ness, and much of the criticism levied against MCII and 
RTN can therefore be applied to the PASS.
The OMERACT-OARSI (OO) criteria32 recognises 
that a response to an intervention may occur in one or 
more different measured outcomes, that is, a multivariate 
response mechanism. In keeping with much of the ortho-
paedic literature, they assume the proposed score has 
been rescaled between 0 and 100,32 and that a responder is 
defined as any individual with (1) a ≥50% relative change 
or a ≥20-point absolute change on one or more responses 
scales or (2) a ≥20% relative change or a ≥10-point abso-
lute change in two or more response scales. Relative 
change is defined as the ratio of the change to the indi-
vidual baseline score multiplied by 100. Unlike the RTN, 
MID or MCII, it is very clear that the thresholds for rela-
tive and absolute changes are based on a panel of expert 
opinions and are fixed.
Despite the variety of existing approaches used to 
identifying responders, there are a number of prob-
lems common to all methods. Common assumptions 
include: (1) each observed outcome is measured 
without error and reflects the true underlying patient’s 
response, test–retest reliability studies indicate that this 
is not a realistic assumption44; (2) regression to the 
mean does not occur and therefore the variance of the 
change score will not be overestimated; (3) floor and 
ceiling effects do not bias estimates of the variance of 
the change score.45
Furthermore, in RTN, specific combinations of means 
and variances may result in a threshold beyond the 
range of the measurement tool, therefore no individuals 
would be defined as responding to a therapy. The MCII 
approach assumes the additional anchoring variable is 
measured without error and the response trajectory is 
distinct from those who are unsatisfied.46 The method 
also assumes a two-parameter logistic function is an 
appropriate model for the cumulative proportional rank 
of patients and change in outcome, and that there is no 
uncertainty in the calculation of the threshold.47 Finally, 
the OO approach considers a response in two or more 
outcomes. However, it does not explicitly describe how 
the correlation between the two outcomes is accounted 
for and fails to recognise that if not modelled appropri-
ately may introduce bias.48–50
The four methods identified have a number of other 
limitations,25 but they are difficult to compare methods 
when presented as distinct approaches.
Embedding them in a unified statistical framework 
makes their underlying assumptions explicit, while high-
lighting their similarities and differences. In addition, it 
provides a framework to incorporate non-linear change, 
measurement error and variability in the timing of 
measurement occasions, all of which are to be expected 
in real word data collections and are critical when 
attempting to asses a patients change at a specified point 
in time.
MLM approach to responsiveness
We now present a general MLM for patient responsive-
ness and show how the four approaches described above 
can be specified as special cases.
Under the assumption of linear change, the measured 
response (y) at the ith occasion for the jth individual is 
modelled as a linear function of time.
 
yij = β0 + u0j +
(
β1 + u1j
)
tij + εij[
u0j
u1j
]
∼ N(0,Ωu), Ωu =
[
σ2u0
σu01 σ
2
u1
]
[
εij
] ∼ N(0,σ2ε)  (1)
where tij is the time at which measurement  was taken 
on individual j, coded as zero at baseline. β0 is the base-
line population average response and u0j represents the 
jth individual difference from the baseline response. 
The sum of β0 + u0j is the estimated individual baseline 
response. β1 represents the population average change 
per unit increase in time and u1j represents the jth indi-
vidual difference from the population average change 
per unit increase in time. The sum of β1 + u1j is the esti-
mated individual average change per unit increase in 
time. Measurement error in the linear trajectory is repre-
sented by εij.
The variance in individual deviations from the popu-
lation average response at baseline and average rate of 
change are σ2u0 and σ
2
u1, respectively. Furthermore, the 
correlation between baseline measurements and rate of 
change can be assumed to be independent or correlated 
by constraining σu01 to be zero or allowing it to be freely 
estimated. The variances of the shrunken residuals uˆ0j 
and uˆ1j, also known as empirical Bayes estimates, are 
typically less than the estimated population variances σˆ2u0 
and σˆ2u1 as they shrink towards the population averages of 
β0 and β1. The extent of the shrinkage depends on the 
number of measurement occasions and the within-indi-
vidual variability, with greater shrinkage as the number 
of measurement occasions decrease and as the within-in-
dividual variance increases. A more detailed discussion 
of MLM can be found in most advanced statistics text-
books.48 51 52
We now describe how the four traditional approaches 
to measuring patient responsiveness can be unified 
into a MLM framework. General benefits of the MLM 
over existing approaches include: (1) with more than 
three measurement occasions, an MLM directly allows 
for measurement error, εij; (2) the use of shrunken 
residuals uˆ0j and uˆ1j allows for regression to the mean 
when predicting an individual’s score53; (3) MLM can 
be extended to include multivariate response models 
which appropriately model the correlation between two 
or more outcomes and (4) MLM allows for variability in 
the timing of measurement occasions. Fundamentally, 
the MLM approach recognises that observed patient 
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responses are subject to error, and therefore the true 
patient’s response following an intervention must be 
estimated.
MLM: return to normal 
To apply the RTN criteria using an MLM approach, we 
first estimate the baseline population SD in individuals 
considered to be abnormal using the model described in 
equation 1. Assuming yij is normally distributed at baseline 
with a population mean β0 and variance σ2u0a100 ·
(
1− α2
)
, 
prediction interval for the baseline measurement can be 
constructed, that is, 
[
β0 − σu0z(1−α2 ) , β0 + σu0z(1−α2 )
]
 where α is 
the type I error rate and z is the critical value from a stan-
dard normal distribution. Importantly, yij is not assumed 
to be measured without error, and therefore estimates of 
σ2u0 are less likely to be biased than using simple methods. 
However, it is important to note that the choice of α is 
entirely that of the researcher, and while α=0.05 (leading 
to z = 1.96 ≈ 2) is common, more or less stringent criteria 
could be applied.
The second step is to estimate the score of the indi-
vidual at time j following surgery and determine if it is 
within the baseline prediction interval. This prediction is 
simply calculated by substituting estimates of β0, β1 , u0j 
and u1j into equation 1, to give the empirical best linear 
unbiased prediction or the jth individual at the ith occa-
sion.54
Finally, to determine whether or not the response of 
the individual following surgery is greater than one would 
attribute to chance alone, that is, the null hypothesis that 
the jth individual's slope is not equal to zero, a test statistic 
similar to RCI should be conducted,
 
(
βˆ1 + uˆ1j
)
/SE
(
βˆ1 + uˆ1j
)
, where SE
(
βˆ1 + uˆ1j
)
=
√
VAR
(
βˆ1
)
+ VAR
(
uˆ1j
)
 
MLM: minimally important difference 
The threshold of minimally important difference can 
also be estimated using an MLM. Similar to RTN, a linear 
model of change is applied, as in equation 1. Then the 
population SD of the baseline response is estimated by 
σu0. By comparing the estimated change for the jth indi-
vidual 
(
βˆ1 + uˆ1j
)
t with the baseline SD, that is, σu0/2, the 
individual can be classed as a responder or not. The MID 
approach does not specifically state whether a test of 
whether an individual’s change scores is less than the MID 
threshold should be conducted, but a test statistic is simply 
constructed as 
((
βˆ1 + uˆ1j
)
t−
(
σˆu0
2
))
/
(
SE
(
βˆ1 + uˆ1j
)
t
)
.
MLM minimal clinically important improvement 
The MLM MCII requires a simple extension of the 
univariate model presented previously (equation 1). The 
outcome of interest is stratified using an external crite-
rion. The stratification is achieved by creating dummy 
variables for those who are unsatisfied/satisfied with 
some aspect of their treatment, for example, x1i takes 
the values 0 and 1 representing unsatisfied and satisfied 
individuals, respectively, and x2i = 1− x1i. These dummy 
variables are then included as additional explanatory 
variables, with no overall model intercept, and interacted 
with t.
 
yij =
(
β0 + u0j
)
x1i +
(
β1 + u1j
)
tijx1i + ε1ijx1i
+
(
β2 + u2j
)
x2i +
(
β3 + u3j
)
tijx2i + ε2ijx2i
u0j
u1j
u2j
u3j
 ∼ N(0,Ωu) : Ωu =

σ2u0
σu01 σ
2
u1
0 0 σ2u2
0 0 σu23 σ
2
u3

ε1ij
ε2ij
 ∼ N(0,Ωε) : Ωε =
σε1
0 σ2ε2

 (2)
Therefore, β0 and β2 are the mean population outcome 
score at baseline for those who are satisfied and unsat-
isfied, respectively, and β1 and β3 are the corresponding 
mean population changes per unit of time. Variances and 
covariances are similarly interpreted for those who are 
satisfied and unsatisfied, respectively. However, that satis-
faction on the external anchoring question is assumed to 
be known without error, and individual effects and errors 
for x1i are uncorrelated with those for x2i because the 
satisfied and unsatisfied categories are mutually exclu-
sive. Whether or not it is desirable to fit a model to both 
satisfied and unsatisfied individuals simultaneously is 
debatable, as only those who are satisfied contribute to the 
definition of MCII. However, we present a simultaneous 
modelling approach to satisfied and unsatisfied individ-
uals as it make the underlying modelling assumptions 
explicit. Furthermore, if the stratification on satisfaction 
status leads to small samples, alternative estimators and 
degree of freedom can be used in an MLM framework to 
account for this, that is, restricted maximum likelihood, 
restricted generalised least squares or adjustments to the 
denominator df.55
Following the prediction of each individual’s trajectory, 
including those unsatisfied with treatment, the second 
stage in the MCII method requires a threshold for deter-
mining responsiveness. Using a similar suggestion to 
Tubach et al,35 the 75th centile of those who are satisfied 
could be used to classify all individuals as responding or 
not. Similar to the MID, there is no suggestion of whether 
a test against the null value of the 75th centile should 
be constructed, but this is easily done within the MLM 
framework.
MLM: OO criteria 
The OO criteria can be similarly extended into a multivar-
iate MLM framework by the inclusion of dummy variables 
and reshaping into a ‘double’ long format with both 
responses stored in a single vector. Figure 1 illustrates the 
data structure for a bivariate model.
Dummy variables, also known as response indicators, 
are used to denote the response options: w1i is coded 1 
for the first measurement outcome (pain) and 0 for the 
second outcome (function), and w2i = 1− w1i. The response 
indicators and their interactions with  are included as 
explanatory variables to obtain the following bivariate 
response model.
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yij =
(
β0 + u0j
)
w1i +
(
β1 + u1j
)
tijw1i + ε1ijw1i
+
(
β2 + u2j
)
w2i +
(
β3 + u3j
)
tijw2i + ε2ijw2i
u0j
u1j
u2j
u3j
 ∼ N(0,Ωu) : Ωu =

σ2u0
σu01 σ
2
u1
σu02 σu12 σ
2
u2
σu03 σu13 σu23 σ
2
u3
[
ε1ij
ε2ij
]
∼ N(0,Ωε) : Ωε =
[
σ2ε1
σε12 σε2
]
 (3)
With a similar functional form to the univariate MLM, 
there are separate population and individual intercepts 
for the first and second outcome (β0, β2 and u0j, u2j, respec-
tively), and separate population and individual slopes 
are estimated for the second outcome 
(
β1, β3 and u1j, u3j
)
. Using an MLM approach, the outcomes are modelled 
jointly, which allows for non-zero covariances between 
the intercepts and slopes of the two responses 
(σu02, σu12, σu03, σu13). The measurement errors for the 
two responses are not assumed to be independent, with 
their covariance directly estimated (σε12).
Finally, the threshold of response must be decided and 
individual trajectories estimated and classified. Similar 
to the other methods, it is relatively simple to construct 
a test statistic for testing whether individual slopes are 
significantly different from the chosen threshold.
Limitations of the MLM approach 
The MLM approach described by equation 1, equations 
2 and 3 assumes that change in the outcome is linearly 
associated with time. The linearity assumption is imposed 
for simplicity. Non-linear changes are easily incorporated 
by including higher order polynomials or using linear or 
non-linear splines.56
The standard MLM approach also fails to directly 
address the issue of floor and ceiling effects. Mixed-re-
sponse multilevel Tobit models allow for such effects and 
provide some adjustment.45 57 Furthermore, while the 
MLM described in equation 2 allows for heterogeneity 
in known groups, they fail to allow for heterogeneity in 
trajectories when the groups are unknown. The use of 
group-based trajectory models or growth mixture models 
in these circumstances may reveal latent (unobserved) 
classes of individuals with distinct patterns of recovery.58
example: the APeX cohort study
Using a mixed cohort of patients undergoing total hip 
replacement (THR) and total knee replacement (TKR),41 
we investigated the performance of the existing and MLM 
approaches using four definitions of responsiveness. A 
simulated data set and code to fit each of these models 
are included in the online supplementary material.
Patients in the APEX cohort completed the Intermittent 
and Constant Osteoarthritis Pain (ICOAP) questionnaire 
before and after surgery at approximately 0, 3, 6 and 12 
months. The date at which the postsurgical question-
naire was completed is recorded in days postsurgery. As 
the name suggests, the ICOAP questionnaire attempts 
to measure intermittent and constant pain.21 The devel-
opers of the tool suggest three ways of summarising the 
scale to generate an intermittent, constant and total 
pain scores (the sum of the intermittent and constant 
pain subscales). The tool is scored between 0 and 100 
and a full description of the ICOAP scale is provided in 
the original validation paper.21 Satisfaction of pain relief 
following surgery was recorded by asking patients to ‘Rate 
the relief of pain provided by (hip/knee) replacement’ 
using a single-item 5-point scale (none, poor, fair, good, 
excellent). We categorised good and excellent as a satis-
factory outcome following surgery.
Using the three methods of aggregation, we present 
estimates of pain at baseline and for change at approx-
imately 3 months postsurgery using existing methods 
(summary statistics) and MLM estimates.
To facilitate comparisons between existing and MLM 
approaches, we assume that all individuals are measured 
at exactly 0, 3, 6 and 12 months. While the existing 
approaches only uses the 0 and 3 month measurements, 
the MLM approach uses a random intercept and random 
slopes across four measurements occasions, using two 
linear splines with a knot point at 3 months to estimate 
the response at 3 months. The inclusion of the second 
spline and the additional two measurement occasions 
allows adjustment for measurement error in the MLM 
approach. Tables 1 and 2 presents results for patients 
undergoing THR and TKR, respectively. The place-
ment of the knot at 3 months was determined by visually 
inspecting the data, similar to the methods by Lenguer-
rand et al.59 With more complex patterns of response an 
iterative model fitting approach is likely to be required 
to determine the optimal knot placement. Modelling 
assumptions were checked using ladder plots and normal 
plots of residuals.
To describe how the responsiveness classification in 
patients changed at 3 months, we used an Exact McNemar 
Figure 1 Illustration of a ‘double’ long data set-up for 
creating a bivariate multilevel modelling.
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test to compare the number of discordant classifications 
generated by existing and MLM approaches.
The APEX study was approved by Southampton and 
South West Hampshire Research Ethics Committee (09/
H0504/94).
resuLts
In all subdivisions of the ICOAP questionnaire, for THR/
TKR patients, the estimates of the baseline mean and 
change scores are approximately equal to those from 
the MLM approaches. In addition, estimates of the SD 
of baseline and change score are overestimated using 
existing approaches in THR/TKR patients. The SD of 
baseline measurements of pain were approximately 3.3 
and 3.75 points greater in existing methods compared 
with MLM methods in THR/TKR patients, respectively, 
while the corresponding SD of change scores are approx-
imately 6.3 and 7 points greater in existing methods 
(see tables 1 and 2, respectively). An example of model 
diagnostics is included in figure 2, which presents the 
observed ICOAP total scores at 0, 3, 6 and 12 months and 
the population average response in ICOAP across time. 
In addition, baseline, change residuals are also presented 
using quantile–quantile plots.
return to normal
Using similar baseline score estimates to the conven-
tional RTN approach and different SDs results in a 
reduction in the threshold of response by approxi-
mately five points in THR/TKR patients. The change 
in threshold is due to smaller estimates of baseline and 
change SDs. When considering the total ICOAP score, 
the MLM approach classifies approximately 10% more 
individuals as responders than existing approaches. It is 
also interesting to note that the threshold of response 
using the existing approach when considering total 
ICOAP score in THR patients is beyond the range of 
the score.
Minimally important difference
Using similar change score estimates and different SDs 
results in an approximately 2-point reduction in the MID 
threshold in THR/TKR patients. The reduced threshold 
results in more individuals being classified as responders 
using the MLM approach.
Minimally clinically important difference
Using the MLM approach in satisfied and unsatisfied 
individuals results in a small increase in the threshold of 
response in comparison with existing approaches. The 
increase in threshold is due to shrunken residuals and 
therefore reduced the variability of predicted change 
scores. The increase in threshold results in a reduced 
number of individuals (3% of THR patients and 6% of 
TKR patients) being identified as responders.
OMerACt-OArsI
The OO approach uses fixed definitions of responsive-
ness. Individual estimates of change from the bivariate 
MLM for constant and intermittent pain are very similar 
to those from the univariate MLM. However, the SD of 
the change score is reduced by approximately 0.5 and 1 
points in constant and intermittent pain comparing the 
univariate and bivariate MLM, respectively, whereas the 
Figure 2 Modelling diagnostic plots. Upper left, ladder plot of observed ICOAP total scores at 0, 3, 6 and 12 months following 
THR and population average trajectory estimated from a MLM, used in RTN and MID analysis, with two linear splines with a 
knot at 3 months. Upper right, lower left and right plots are quantile–quantile plots of the residual distribution of random effects 
estimated from an MLM with two linear splines with a knot at 3 months. ICOAP, intermittent and constant osteoarthritis pain; 
MID, minimally important difference; MLM, multilevel model; RTN, return to normal; THR, total hip replacement.
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SD of baseline score approximately the same. Despite 
the larger absolute threshold of 20 and 10 points for 
changes in one or two items, respectively, that is, larger 
than MID, there is an increase in the proportion of indi-
viduals identified as responding. The increase is partly 
due to the use of the relative change threshold and the 
reduced variability in change in comparison with the 
univariate MLM using MID definition of responsive-
ness.
responsiveness classification
The effect of using a MLM approach to defining patient 
responsiveness compared with existing approaches 
is presented in tables 3 and 4 for THR and TKR 
patients,respectively. While the use of MLM provides 
refined thresholds of responsiveness, it fundamentally 
changes the way individuals are classified due to adjust-
ment for measurement error, regression to the mean 
and ability to conduct refined tests. Patients previously 
defined as non-responding using existing methods are 
now responders (positive change) in MLM approaches, 
and similarly, patients defined as responders using 
existing methods are classified as non-responders 
(negative change) in MLM (see figure 3 for graphical 
illustration). MLM MID and OO methods appear to 
be most consistent in the reclassification of patients 
increasing the number of patients defined as non-re-
sponders using existing methods as responders in MLM 
approaches, whereas MLM RTN and MCII provide a 
more fundamental change the classifications of patient 
responsiveness.
Table 3 Cross-classification of responsiveness status in THR patients using existing and MLM model approaches to 
responsiveness: RTN, MID, MCII and OO criteria
Total hip replacement
ICOAP
Multilevel model
RTN MID MCII OO
N. resp Resp N. resp Resp N. resp Resp N. resp Resp
Existing Total N. resp 36 26 5 12 52 7 – –
Resp 10 138 0 193 17 134 – –
Chronic N. resp 210 0 24 9 52 6 – –
Resp 0 0 0 177 4 148 – –
Intermittent N. resp 33 30 6 15 50 10 – –
Resp 8 139 0 189 19 131 – –
Chronic and
intermittent
N. resp – – – – – – 1 15
Resp – – – – – – 0 194
Bold cells indicate significance (p≤0.05) of discordant pairs using Exact McNemar test.
ICOAP, Intermittent and Constant Osteoarthritis Pain; MCII, minimally clinical important improvement; MID, minimally important difference; 
MLM, multilevel model; N. resp, non-responders; OO, OMERACT OARSI; Resp, responders; RTN, return to normal.
Table 4 Cross-classification of responsiveness status in TKR patients using existing and MLM model approaches to 
responsiveness: RTN, MID, MCII and OO criteria
TKR
ICOAP
Multilevel model
RTN MID MCII OO
N. resp Resp N. resp Resp N. resp Resp N. resp Resp
Existing Total N. resp 81 27 13 26 64 7 – –
Resp 11 71 0 151 21 98 – –
Chronic N. resp 92 13 19 29 61 7 – –
Resp 28 57 0 142 24 98 – –
Intermittent N. resp 69 44 9 31 63 10 – –
Resp 3 74 1 149 23 94 – –
Chronic and
intermittent
N. resp – – – – – – 3 33
Resp – – – – – – 0 154
Bold cells indicate significance (p≤0.05) of discordant pairs using Exact McNemar test.
ICOAP, Intermittent and Constant Osteoarthritis Pain; MCII, minimally clinical important improvement; MID, minimally important difference; 
MLM, multilevel model; N. resp, non-responders; OO, OMERACT OARSI; Resp, responders; RTN, return to normal; TKR, total knee 
replacement. 
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DIsCussIOn
The primary purpose of a responsiveness analysis is 
to convey the variability of an individual’s chances of 
perceiving an improvement following a treatment. 
Existing approaches appear to be distinct from one 
another, and the precise relationship between existing 
methods was unclear.
We have clearly shown how four commonly used 
approaches to estimating patient responsiveness can be 
incorporated into the unified statistical framework of 
MLM. Their translation into unified framework makes 
many of the assumption (linearity of response, heteroge-
neity in the timing of measures, multiple measurements) 
underpinning existing approaches clear. The applica-
tion of patient responsiveness models in a cohort of 
orthopaedic patients illustrates how SDs of baseline and 
change scores in existing approaches are overestimated 
in comparison with the MLM approach. Thresholds for 
defining responders from MLM are lower when based 
on SD, and therefore existing approaches to RTN and 
MID may appear to provide a worse case scenario with 
regards the efficacy of a treatment or therapy. Similarly, 
responsiveness approaches based on the distribution of 
predicted change scores (MCII) are higher in MLM, and 
therefore existing thresholds could be described as a best-
case scenario in comparison with existing approaches. 
However, the reclassification of patients using the MLM 
is more fundamental than increasing or reducing the 
threshold to determine responsiveness, the implicit 
adjustments for measurement error and regression to the 
mean change which patients are defined as responding 
or not.
MLM are not the panacea of patient responsiveness 
methods; however, they do highlight implicit assumptions 
in existing approaches and provide sensible adjustments 
for measurement error, regression to the mean and 
heterogeneity in the timing of measurements in clinical 
studies.
From a clinical perspective, it is very clear there are 
differences in the outcomes at 3 months following THR 
and TKR, while patient’s baseline level of pain is similar 
between THR and TKR, the response to surgery is less and 
consistently less (lower variability) for all pain domains. 
Similarly, we have previously observed different patterns 
of pain, in relation to pain at rest and pain on move-
ment,60 yet the mechanisms underpinning theses effects 
are unclear and require more research, but this empha-
sises the necessity to treat hip and knee osteoarthritis as 
separate disease states.
strengths and limitations
One of the key benefits of adopting a MLM approach 
when defining clinically meaningful change is the 
improved estimation of individual change by the greater 
flexibility in the MLM framework. Specifically, MLM 
do not assume the response is measured without error, 
Figure 3 Change in responder classification using an RTN definition comparing existing approaches to MLM approach 
using the ICOAP total score in patients following THR. Upper left panel illustrates observed trajectories for patients whose 
responsiveness classification changes using an MLM approach to estimating responsiveness. Lower left panel illustrates 
the observed and predicted trajectories of ICOAP total score in patients positively reclassified as responders compared with 
existing approaches. Lower right panel illustrates the observed and predicted trajectories of ICOAP total score in patients 
negatively reclassified as non-responders compared with existing approaches. ICOAP, Intermittent and Constant Osteoarthritis 
Pain; MLM, multilevel model; RTN, return to work; THR, total hip replacement. 
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they adjust for regression to the mean, the trajectory of 
recovery is not constrained to be linear and data from 
multiple measurements and variability in the timing of 
those measurement occasions can also be incorporated 
into the model. Furthermore, assuming the underlying 
MLM adequately represents the true causal mechanism, 
parameter estimates, SDs and SEs will be unbiased in 
comparison with existing approaches.
Furthermore, the unification of existing approaches 
into a MLM framework clearly shows the relationship 
between the four different approaches. For example, 
RTN and MID share the same underlying model. MCII is 
also the same at RTN/MID if you assume the baseline and 
change scores are the same across strata of unsatisfied/
satisfied patients. Similarly, the model underlying OO 
approach is the same as the RTN/MID approach if you 
assume independence in the measured outcomes of the 
two trajectories and the error term.
Despite the numerous benefits of adopting an MLM 
approach, it is not to say it is without some limitations. 
MLMs are technically more demanding than existing 
formulations of patient responsiveness, and while there 
are no theoretical limits on how large or small samples 
have to be, model convergence is not guaranteed. The 
need to use appropriate estimation methods38 or denom-
inator degrees of freedom55 when calculating standard 
errors also requires consideration. Furthermore, it is 
important to perform model diagnostic to check the data 
fit with the model. MLM does not improve the arbitrary 
placement of the thresholds that define responsiveness 
in comparison with existing methods, and despite the 
improved trajectory modelling, it is currently unclear 
if the refined definitions correlate more strongly with 
patient expectations, functional data, long-term self-re-
ported outcomes or hard endpoints such as mortality 
and revision. Further research externally validating the 
classification using patient groups, expert opinion61 or 
functional data may demonstrate improved classifica-
tion of those responding to treatment in comparison 
with existing methods. In addition, the use of multiple 
measurements in MLM primarily restricts the method to 
a research setting.
It is clear the MLMs provide considerable advantages 
over existing approaches to identifying patients who 
respond to a treatment. Consequently, the proportion of 
individuals thought not to be responding to treatment 
may be smaller than previously thought. Using the rede-
fined definition may reduce the number of individuals 
misclassified as non-responders and improve the predic-
tion of those individuals who are likely to respond to 
treatment.
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